This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsieh, C.-L. Articles by Chung, L. W. K. Search for Related Content PubMed PubMed Citation Articles by Hsieh, C.-L. Articles by Chung, L. W. K.

A Novel Targeting Modality to Enhance Adenoviral Replication by Vitamin D₃ in Androgen-independent Human Prostate Cancer Cells and Tumors¹

Department of Urology, Molecular Urology and Therapeutics Program, Emory University School of Medicine, Atlanta, Georgia 30322 [C-L. H., H. E. Z., L. W. K. C.]; Department of Urology, Molecular Urology and Therapeutics Program, University of Virginia School of Medicine, Charlottesville, Virginia 22908 [C-L. H., L. Y., L. M., F. Y., H. E. Z., L. W. K. C.]; Department of Urology, Indiana University Cancer Pavilion, Indianapolis, Indiana 46202 [C. K.]; and Department of Pathology, Jilin University, 130031 Jilin, China [H. Y.]

We report the development of a novel replication-competent adenoviral vector, Ad-hOC-E1, containing a single bidirectional human osteocalcin (hOC) promoter to drive both the early viral E1A and E1B gene. This vector selectively replicated in OC-expressing but not non-OC-expressing cells, with viral replication enhanced at least 10-fold on vitamin D₃ exposure. Both the artificial TATA-box and hOC promoter element in this bidirectional promoter construct were controlled by a common OC regulatory element which selectively activated OC expression in cells. The expression ofE1A and E1B gene by Ad-hOC-E1 can be markedly induced by vitamin D₃. Unlike Ad-sPSA-E1, an adenoviral vector with viral replication controlled by a strong super prostate-specific antigen (sPSA) promoter which only replicates in PSA-expressing cells with androgen receptor (AR), Ad-hOC-E1 retarded the growth of both androgen-dependent and androgen-independent prostate cancer cells irrespective of their basal level of AR and PSA expression. A single i.v. administration of 2 x 10⁹ plaque-forming units of Ad-hOC-E1 inhibited the growth of previously established s.c. DU145 tumors (an AR- and PSA-negative cell line). Viral replication is highly enhanced by i.p. administration of vitamin D₃. Ultimately, enhancing Ad-hOC-E1 viral replication by vitamin D₃ may be used clinically to treat localized and osseous metastatic prostate cancer in men.

This article has been cited by other articles:

				X. Li, J. Zhang, H. Gao, E. Vieth, K.-H. Bae, Y.-P. Zhang, S.-J. Lee, S. Raikwar, T. A. Gardner, G. D. Hutchins, et al. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by {alpha}-lactalbumin promoter Mol. Cancer Ther., December 1, 2005; 4(12): 1850 - 1859. [Abstract] [Full Text] [PDF]

				X. Li, Y.-P. Zhang, H.-S. Kim, K.-H. Bae, K. M. Stantz, S.-J. Lee, C. Jung, J. A. Jimenez, T. A. Gardner, M.-H. Jeng, et al. Gene Therapy for Prostate Cancer by Controlling Adenovirus E1a and E4 Gene Expression with PSES Enhancer Cancer Res., March 1, 2005; 65(5): 1941 - 1951. [Abstract] [Full Text] [PDF]

				R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]